Leadership

Co-founder of Acuity Pharmaceuticals (merged to form OPKO Health, NYSE: OPK). Co-founder of Avdarna Therapeutics, Aikium, and Promedior (acquired by Roche for over $1 billion). Co-founder and CTO of Aviceda Therapeutics, raised $207M for Phase III trials. Pioneer in anti-VEGF therapeutics (Avastin, Lucentis, Eylea) and siRNA technology. Principal Investigator in over 160 clinical trials resulting in multiple FDA drug approvals. B.A. in Computer Science from Brown University, M.D. from UMass Chan Medical School, Postdoctoral fellowship and ophthalmology residency at Harvard Medical School and Vitreoretinal surgical fellowship at University of Pennsylvania.

Dr. Feng is the Founder and Chief Executive Officer of Vesicor Therapeutics, Inc. Dr. Feng has over 30 years’ experience as a research scientist in cell and molecular biology. He has a strong background in studies of the cell cycle, DNA replication, regulation of gene expression, gene transfer with recombinant retrovirus, DNA-protein interactions, expertise in cloning, cell type-specific gene expression and gene transfection and transduction in mammalian systems. Dr. Feng has conducted research at the National Laboratory of Molecular Oncology at the Chinese Academy of Medical Sciences (CAMS) in Beijing, at the Saban Institute at Childrens Hospital of Los Angeles, at UCLA, and the Beckman Research Institute at City of Hope National Medical Center. In 2008, Dr. Feng founded RNTein Biotech Lab with the goal of commercializing microvesicle-based therapeutics. He has published extensively in multiple scientific journals. Dr. Feng has a BS degree in medical sciences from Anhui Medical College (Hefei, Anhui, China), a M.S. degree in biochemistry from the Cancer Institute of the Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) in Beijing, and a Ph.D. in molecular biology from CAMS and PUMC. He was a postdoctoral fellow in the Department of Hematology and Oncology at Childrens Hospital of Los Angeles and completed further postdoctoral research in the Department of Molecular and Medical Pharmacology at UCLA.

CEO and Director of Pioneer Acquisition Corp (NASDAQ: PACH). Over 35 years of healthcare executive experience in operations and business evaluation. Principal at GreenRock Capital. Former Director of Nutex Health (Nasdaq: NUTX) and Apollo Medical Holdings, Inc. (Nasdaq: ASTH). Previously CEO of Keck Hospital of USC and CFO of UCLA Health Sciences. Held CFO roles at Beth Israel Deaconess, Tufts Medical Center, and ApolloMed. B.S. in Accounting & Business/Management from Boston University and MHA from Duke University.

Mr. Hosseinion has served as the Chief Operating Officer of Vesicor since February 2023. Prior to joining Vesicor, he was an equity owner and executive of a privately-held blockchain technology startup, where he lead the strategic and operational aspects of the company. Mr. Hosseinion received a B.S. in Biology from Pitzer College.